IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential ...

A comprehensive study of effective and resistant responses to a kidney cancer anti-PD-1 therapy found specific immune ...

Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics ...

Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...